Clinical Trial

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate use of lovastatin, a drug that may lower CAV-1 levels, in order to increase HER2 expression on cells and enhance the uptake and efficacy of trastuzumab deruxtecan (T-DXd) in HER2-low and ultralow advanced metastatic breast cancer. Trastuzumab deruxtecan (T-DXd) is an FDA approved antibody drug conjugate for HER2-low and ultralow breast cancer and lovastatin is a cholesterol lowering agent.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-29.
Trial Details
NCT Number NCT07619365
Lead Sponsor Washington University School of Medicine
Collaborators: National Cancer Institute (NCI)
Conditions Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
Enrollment 60 participants
Start Date 2026-08-31
Primary Completion 2030-08-31 (estimated)
Study Completion 2031-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-08